Stockadora

8-K filings / November 13, 2026

Acurx Pharmaceuticals, Inc.: A change of officers or directors

Acurx Pharmaceuticals, Inc. filed a current report (Form 8-K) with the SEC on November 13, 2026. It reports a change of officers or directors.

AI-written from the facts below

In plain English

Joseph C. Scodari is leaving the board of directors, effective November 13, 2026. This board change is reported under Item 5.02 of Form 8-K, the section covering directors and senior officers who leave or are appointed.

What each sentence states
“Joseph C. Scodari is leaving the board of directors, effective November 13, 2026.”
  • Item 5.02: Joseph C. Scodari leaves the board of directors, effective November 13, 2026.
“This board change is reported under Item 5.02 of Form 8-K, the section covering directors and senior officers who leave or are appointed.”
  • Item 5.02 of Form 8-K covers directors and senior officers who leave or are appointed.
  • Item 5.02: Joseph C. Scodari leaves the board of directors, effective November 13, 2026.
Written by an AI model from the facts on this page only; code and a second model checked every sentence against them.

Item 5.02

Officers and directors

  • Leaves Joseph C. Scodari, DirectorEffective November 13, 2026 From the filing
    Source
    “On November 12, 2026, Joseph C. Scodari, a member of the Board of Directors (the “Board”) of Acurx Pharmaceuticals, Inc. (the “Company”) since 2021, provided the Company with notice of his intention to retire from the Board, effective November 13, 2026.”
    Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov

Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.